Unicycive Therapeutics Inc (UNCY) FinancialsUNCYFinancialUnicycive Therapeutics Inc

Evaluating the bottom line, Unicycive Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -101.07%, provide a clear picture of how effectively UNCY converts its operational activities into shareholder value.

In the context of the broader market, UNCY competes directly with industry leaders such as MOLN and EQ. With a market capitalization of $153.48M, it holds a significant position in the sector. When comparing efficiency, UNCY's gross margin of N/A stands against MOLN's N/A and EQ's N/A. Such benchmarking helps identify whether Unicycive Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Unicycive has reported negative net income for several quarters, with Q2 2026 showing a loss of $1.722 million. The company's current ratio is strong at 3.81, indicating good short-term liquidity, but it has a forward P/E of 3.4447, reflecting concerns about profitability.